Mechanism

How it works

PT-141 acts as an agonist at melanocortin receptors MC3R and MC4R in the central nervous system, particularly in the hypothalamus and limbic system. Activation of these receptors triggers downstream dopaminergic and oxytocinergic signaling pathways that modulate sexual desire, arousal, and motivation. This central mechanism differentiates it from vasodilatory agents such as sildenafil, as PT-141 directly addresses the neurobiological component of sexual dysfunction.

Reported in research

Benefits

Clinically proven to increase sexual desire and arousal in women with HSDD (FDA-approved as Vyleesi)
Effective in men with erectile dysfunction, including those who do not respond to PDE5 inhibitors
Works via central nervous system pathways, addressing psychological/neurological components of sexual dysfunction
Relatively rapid onset (30–60 minutes) allowing on-demand dosing

Context, not a prescription

Dosing

Typical range: 1–2 mg per dose (FDA-approved dose is 1.75 mg; research protocols vary from 0.5–2 mg) (Subcutaneous, Nasal)
Cycle length: On-demand; not typically used in continuous cycles. Maximum 1 dose per 24 hours, no more than 8 doses per month recommended.
Half-life: ~2.7 hours (terminal half-life ~120 hours due to extended tissue distribution)

Safety

Side effects & contraindications

Possible side effects

Nausea and vomiting (most common, reported in ~40% of subjects in clinical trials)
Flushing and hot flashes
Transient hyperpigmentation of skin with repeated dosing
Headache
Transient increases in blood pressure (systolic and diastolic)
Injection site reactions (erythema, bruising)

Contraindications

Cardiovascular disease or high risk of major adverse cardiovascular events (due to transient blood pressure elevation)
Pregnancy or breastfeeding
Concurrent use with naltrexone or other opioid antagonists may reduce efficacy
History of severe nausea/vomiting disorders
Uncontrolled hypertension

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Users commonly report increased sexual desire and arousal, heightened sensitivity, and improved motivation for sexual activity. Some men report firm, spontaneous erections. Women report increased lubrication and desire.

How it works

Imagine your sex drive is like the volume knob on a stereo — PT-141 goes directly to the control panel in your brain and turns the volume up, rather than just amplifying the speakers (blood vessels) downstream.

After injection, PT-141 travels to the brain and binds to receptors in areas that regulate desire, mood, and motivation. Within 30–60 minutes, many users notice increased arousal and sexual interest. It does not require sexual stimulation to work, though stimulation enhances the effect.

What to expect

Effects typically begin within 30–60 minutes after subcutaneous injection and last 4–12 hours for most users.

First 30–60 minutes: Peptide is absorbed and begins activating brain receptors — some nausea or flushing may occur.
Hours 1–6: Peak sexual arousal and desire effects; most users report the strongest response in this window.
After 6–12 hours: Effects gradually subside; no lingering hormonal impact from a single dose.

Good to know

Take an anti-nausea medication (e.g., ondansetron) 30 minutes before dosing to reduce nausea
Start with a lower dose (0.5–1 mg) to assess tolerance before using the full dose

Staying safe

Nausea — often within 1 hour of dosing, usually passes within 2–3 hours
Flushing or warm sensation in the face and body
Mild headache

Avoid if you have:

People with heart disease or high blood pressure
Pregnant or breastfeeding individuals
People with a history of severe nausea or vomiting disorders

Overview

Mechanistically, PT-141 elevates dopaminergic activity in the nucleus accumbens, enhancing incentive salience (desire/motivation) toward sexual stimuli. In males, this translates to psychogenic erections mediated independently of peripheral nitric oxide pathways. In females, increased genital vasocongestion and lubrication occur alongside subjective desire improvement. Long-term dosing (>8 doses/month) has been associated with focal dermal melanocyte stimulation via MC1R, leading to reversible hyperpigmentation.

How it works

PT-141 functions like a selective key for a master lock in the hypothalamus — unlocking a cascade of neurotransmitter releases (dopamine, oxytocin) that the limbic system uses to generate motivated sexual behavior, analogous to upstream transcription factor activation that initiates a downstream gene expression program.

Following subcutaneous administration, PT-141 achieves peak plasma concentrations (Tmax) at approximately 1 hour with a distribution half-life of ~1 hour and terminal half-life of approximately 120 hours due to peripheral tissue binding. It crosses the blood-brain barrier and demonstrates preferential accumulation in hypothalamic regions. The transient blood pressure elevation (mean systolic +6 mmHg, mean diastolic +3 mmHg) is believed to be mediated through peripheral MC1R and MC3R receptor engagement and resolves within 12 hours. Metabolized primarily via peptide hydrolysis.

Onset & timeline

Pharmacodynamic effects begin within 30–60 minutes of subcutaneous injection, correlating with brain Tmax. The sexual arousal response appears dose-dependent between 0.5–2 mg, with maximal effect in the 1–2 mg range. Duration of subjective arousal effects is approximately 4–12 hours.

Days 1–3 (initial dosing): Absorption is rapid (Tmax ~1 hr). MC4R-mediated hypothalamic activation initiates dopaminergic and oxytocinergic signaling. Peak subjective arousal effects within 1–2 hours. BP elevation detectable. Nausea most pronounced with first few doses.
Weeks 1–4 (intermittent use): No tachyphylaxis observed in clinical trial data at appropriate dosing intervals (≥24 hrs between doses). Nausea tends to diminish with repeated use in some subjects. Consistent improvement in FSFI scores (desire domain) observed in Phase III RECONNECT trials.
Months 1–3 (extended intermittent use): Continued efficacy in responders. Monitor for hyperpigmentation, especially in individuals with Fitzpatrick skin types III–VI. Long-term cardiovascular safety data from clinical trials (up to 52-week extension studies) showed no cumulative cardiovascular risk signal beyond individual dose BP effects.

Getting the most from it

Pre-administer 4 mg ondansetron (oral or sublingual) 30 minutes prior to PT-141 injection to substantially reduce nausea incidence (supported by clinical practice in Vyleesi prescribing guidelines)
Monitor blood pressure in at-risk patients for 12 hours post-dose
Use minimum effective dose (1 mg) and avoid exceeding 8 doses/month to limit cumulative MC1R stimulation
Rotate injection sites to minimize local pigmentation

Common side effects

Nausea: incidence ~40% in Phase III trials (RECONNECT studies), likely mediated by MC3R/MC4R activation in the dorsal vagal complex and area postrema
Flushing: peripheral MC1R and MC3R-mediated vasodilation, reported in ~20% of subjects
Transient hypertension: mean increase of 6/3 mmHg systolic/diastolic; resolves within 12 hours

Mechanism of action

PT-141 is a cyclic heptapeptide analog of alpha-MSH (alpha-melanocyte-stimulating hormone) that selectively binds to and activates melanocortin receptor subtypes MC3R and MC4R. MC4R in particular is highly expressed in the paraventricular nucleus (PVN) of the hypothalamus. Receptor activation triggers Gs protein-coupled adenylyl cyclase signaling, elevating intracellular cAMP and activating downstream PKA pathways. This modulates dopaminergic tone in mesolimbic reward circuits and facilitates oxytocin release, both of which are central mediators of sexual motivation and copulatory behavior. MC3R activation may contribute to additional modulatory effects on energy balance and mood.

Following subcutaneous administration, PT-141 achieves peak plasma concentrations (Tmax) at approximately 1 hour with a distribution half-life of ~1 hour and terminal half-life of approximately 120 hours due to peripheral tissue binding. It crosses the blood-brain barrier and demonstrates preferential accumulation in hypothalamic regions. The transient blood pressure elevation (mean systolic +6 mmHg, mean diastolic +3 mmHg) is believed to be mediated through peripheral MC1R and MC3R receptor engagement and resolves within 12 hours. Metabolized primarily via peptide hydrolysis.

Pharmacodynamics

Pharmacodynamic effects begin within 30–60 minutes of subcutaneous injection, correlating with brain Tmax. The sexual arousal response appears dose-dependent between 0.5–2 mg, with maximal effect in the 1–2 mg range. Duration of subjective arousal effects is approximately 4–12 hours.

Mechanistically, PT-141 elevates dopaminergic activity in the nucleus accumbens, enhancing incentive salience (desire/motivation) toward sexual stimuli. In males, this translates to psychogenic erections mediated independently of peripheral nitric oxide pathways. In females, increased genital vasocongestion and lubrication occur alongside subjective desire improvement. Long-term dosing (>8 doses/month) has been associated with focal dermal melanocyte stimulation via MC1R, leading to reversible hyperpigmentation.

Timeline

Days 1–3 (initial dosing): Absorption is rapid (Tmax ~1 hr). MC4R-mediated hypothalamic activation initiates dopaminergic and oxytocinergic signaling. Peak subjective arousal effects within 1–2 hours. BP elevation detectable. Nausea most pronounced with first few doses.
Weeks 1–4 (intermittent use): No tachyphylaxis observed in clinical trial data at appropriate dosing intervals (≥24 hrs between doses). Nausea tends to diminish with repeated use in some subjects. Consistent improvement in FSFI scores (desire domain) observed in Phase III RECONNECT trials.
Months 1–3 (extended intermittent use): Continued efficacy in responders. Monitor for hyperpigmentation, especially in individuals with Fitzpatrick skin types III–VI. Long-term cardiovascular safety data from clinical trials (up to 52-week extension studies) showed no cumulative cardiovascular risk signal beyond individual dose BP effects.

Comparisons

PT-141 (Bremelanotide) — effectiveness High, safety Moderate, cost $$, Medium to use
Flibanserin (Addyi) — effectiveness Moderate, safety Moderate, cost $$$, Low to use
Sildenafil (Viagra) — effectiveness High, safety Good, cost $, High to use

Adverse effects

Common:

Nausea: incidence ~40% in Phase III trials (RECONNECT studies), likely mediated by MC3R/MC4R activation in the dorsal vagal complex and area postrema
Flushing: peripheral MC1R and MC3R-mediated vasodilation, reported in ~20% of subjects
Transient hypertension: mean increase of 6/3 mmHg systolic/diastolic; resolves within 12 hours

Rare:

Focal hyperpigmentation: reported in ~1% of subjects with repeated monthly dosing; involves MC1R-mediated melanocyte activation; typically reversible on cessation
Severe nausea/emesis requiring antiemetic intervention: <5% of subjects in clinical trials

Contraindications & risk mitigation

Contraindicated in:

Patients with established cardiovascular disease or MACE risk factors due to transient hemodynamic changes
Patients on antihypertensive therapy where a transient 12-hour BP elevation could be clinically significant
Patients with a personal or family history of melanoma due to MC1R-mediated melanocyte stimulation (theoretical risk; not confirmed causally)
Concurrent use of medications that significantly prolong QTc interval

Pre-administer 4 mg ondansetron (oral or sublingual) 30 minutes prior to PT-141 injection to substantially reduce nausea incidence (supported by clinical practice in Vyleesi prescribing guidelines)
Monitor blood pressure in at-risk patients for 12 hours post-dose
Use minimum effective dose (1 mg) and avoid exceeding 8 doses/month to limit cumulative MC1R stimulation
Rotate injection sites to minimize local pigmentation

Qué hace

Users commonly report increased sexual desire and arousal, heightened sensitivity, and improved motivation for sexual activity. Some men report firm, spontaneous erections. Women report increased lubrication and desire.

Cómo funciona

Imagine your sex drive is like the volume knob on a stereo — PT-141 goes directly to the control panel in your brain and turns the volume up, rather than just amplifying the speakers (blood vessels) downstream.

After injection, PT-141 travels to the brain and binds to receptors in areas that regulate desire, mood, and motivation. Within 30–60 minutes, many users notice increased arousal and sexual interest. It does not require sexual stimulation to work, though stimulation enhances the effect.

Qué esperar

Effects typically begin within 30–60 minutes after subcutaneous injection and last 4–12 hours for most users.

First 30–60 minutes: Peptide is absorbed and begins activating brain receptors — some nausea or flushing may occur.
Hours 1–6: Peak sexual arousal and desire effects; most users report the strongest response in this window.
After 6–12 hours: Effects gradually subside; no lingering hormonal impact from a single dose.

Bueno saber

Take an anti-nausea medication (e.g., ondansetron) 30 minutes before dosing to reduce nausea
Start with a lower dose (0.5–1 mg) to assess tolerance before using the full dose

Manteniéndose seguro

Nausea — often within 1 hour of dosing, usually passes within 2–3 hours
Flushing or warm sensation in the face and body
Mild headache

Evitar si tienes:

People with heart disease or high blood pressure
Pregnant or breastfeeding individuals
People with a history of severe nausea or vomiting disorders

Descripción general

Mechanistically, PT-141 elevates dopaminergic activity in the nucleus accumbens, enhancing incentive salience (desire/motivation) toward sexual stimuli. In males, this translates to psychogenic erections mediated independently of peripheral nitric oxide pathways. In females, increased genital vasocongestion and lubrication occur alongside subjective desire improvement. Long-term dosing (>8 doses/month) has been associated with focal dermal melanocyte stimulation via MC1R, leading to reversible hyperpigmentation.

Cómo funciona

PT-141 functions like a selective key for a master lock in the hypothalamus — unlocking a cascade of neurotransmitter releases (dopamine, oxytocin) that the limbic system uses to generate motivated sexual behavior, analogous to upstream transcription factor activation that initiates a downstream gene expression program.

Following subcutaneous administration, PT-141 achieves peak plasma concentrations (Tmax) at approximately 1 hour with a distribution half-life of ~1 hour and terminal half-life of approximately 120 hours due to peripheral tissue binding. It crosses the blood-brain barrier and demonstrates preferential accumulation in hypothalamic regions. The transient blood pressure elevation (mean systolic +6 mmHg, mean diastolic +3 mmHg) is believed to be mediated through peripheral MC1R and MC3R receptor engagement and resolves within 12 hours. Metabolized primarily via peptide hydrolysis.

Inicio y cronología

Pharmacodynamic effects begin within 30–60 minutes of subcutaneous injection, correlating with brain Tmax. The sexual arousal response appears dose-dependent between 0.5–2 mg, with maximal effect in the 1–2 mg range. Duration of subjective arousal effects is approximately 4–12 hours.

Days 1–3 (initial dosing): Absorption is rapid (Tmax ~1 hr). MC4R-mediated hypothalamic activation initiates dopaminergic and oxytocinergic signaling. Peak subjective arousal effects within 1–2 hours. BP elevation detectable. Nausea most pronounced with first few doses.
Weeks 1–4 (intermittent use): No tachyphylaxis observed in clinical trial data at appropriate dosing intervals (≥24 hrs between doses). Nausea tends to diminish with repeated use in some subjects. Consistent improvement in FSFI scores (desire domain) observed in Phase III RECONNECT trials.
Months 1–3 (extended intermittent use): Continued efficacy in responders. Monitor for hyperpigmentation, especially in individuals with Fitzpatrick skin types III–VI. Long-term cardiovascular safety data from clinical trials (up to 52-week extension studies) showed no cumulative cardiovascular risk signal beyond individual dose BP effects.

Cómo aprovecharlo al máximo

Pre-administer 4 mg ondansetron (oral or sublingual) 30 minutes prior to PT-141 injection to substantially reduce nausea incidence (supported by clinical practice in Vyleesi prescribing guidelines)
Monitor blood pressure in at-risk patients for 12 hours post-dose
Use minimum effective dose (1 mg) and avoid exceeding 8 doses/month to limit cumulative MC1R stimulation
Rotate injection sites to minimize local pigmentation

Efectos secundarios comunes

Nausea: incidence ~40% in Phase III trials (RECONNECT studies), likely mediated by MC3R/MC4R activation in the dorsal vagal complex and area postrema
Flushing: peripheral MC1R and MC3R-mediated vasodilation, reported in ~20% of subjects
Transient hypertension: mean increase of 6/3 mmHg systolic/diastolic; resolves within 12 hours

Mecanismo de acción

PT-141 is a cyclic heptapeptide analog of alpha-MSH (alpha-melanocyte-stimulating hormone) that selectively binds to and activates melanocortin receptor subtypes MC3R and MC4R. MC4R in particular is highly expressed in the paraventricular nucleus (PVN) of the hypothalamus. Receptor activation triggers Gs protein-coupled adenylyl cyclase signaling, elevating intracellular cAMP and activating downstream PKA pathways. This modulates dopaminergic tone in mesolimbic reward circuits and facilitates oxytocin release, both of which are central mediators of sexual motivation and copulatory behavior. MC3R activation may contribute to additional modulatory effects on energy balance and mood.

Following subcutaneous administration, PT-141 achieves peak plasma concentrations (Tmax) at approximately 1 hour with a distribution half-life of ~1 hour and terminal half-life of approximately 120 hours due to peripheral tissue binding. It crosses the blood-brain barrier and demonstrates preferential accumulation in hypothalamic regions. The transient blood pressure elevation (mean systolic +6 mmHg, mean diastolic +3 mmHg) is believed to be mediated through peripheral MC1R and MC3R receptor engagement and resolves within 12 hours. Metabolized primarily via peptide hydrolysis.

Farmacodinamia

Pharmacodynamic effects begin within 30–60 minutes of subcutaneous injection, correlating with brain Tmax. The sexual arousal response appears dose-dependent between 0.5–2 mg, with maximal effect in the 1–2 mg range. Duration of subjective arousal effects is approximately 4–12 hours.

Mechanistically, PT-141 elevates dopaminergic activity in the nucleus accumbens, enhancing incentive salience (desire/motivation) toward sexual stimuli. In males, this translates to psychogenic erections mediated independently of peripheral nitric oxide pathways. In females, increased genital vasocongestion and lubrication occur alongside subjective desire improvement. Long-term dosing (>8 doses/month) has been associated with focal dermal melanocyte stimulation via MC1R, leading to reversible hyperpigmentation.

Cronología

Days 1–3 (initial dosing): Absorption is rapid (Tmax ~1 hr). MC4R-mediated hypothalamic activation initiates dopaminergic and oxytocinergic signaling. Peak subjective arousal effects within 1–2 hours. BP elevation detectable. Nausea most pronounced with first few doses.
Weeks 1–4 (intermittent use): No tachyphylaxis observed in clinical trial data at appropriate dosing intervals (≥24 hrs between doses). Nausea tends to diminish with repeated use in some subjects. Consistent improvement in FSFI scores (desire domain) observed in Phase III RECONNECT trials.
Months 1–3 (extended intermittent use): Continued efficacy in responders. Monitor for hyperpigmentation, especially in individuals with Fitzpatrick skin types III–VI. Long-term cardiovascular safety data from clinical trials (up to 52-week extension studies) showed no cumulative cardiovascular risk signal beyond individual dose BP effects.

Comparaciones

PT-141 (Bremelanotide) — efectividad High, seguridad Moderate, costo $$, Medium de usar
Flibanserin (Addyi) — efectividad Moderate, seguridad Moderate, costo $$$, Low de usar
Sildenafil (Viagra) — efectividad High, seguridad Good, costo $, High de usar

Efectos adversos

Comunes:

Nausea: incidence ~40% in Phase III trials (RECONNECT studies), likely mediated by MC3R/MC4R activation in the dorsal vagal complex and area postrema
Flushing: peripheral MC1R and MC3R-mediated vasodilation, reported in ~20% of subjects
Transient hypertension: mean increase of 6/3 mmHg systolic/diastolic; resolves within 12 hours

Raros:

Focal hyperpigmentation: reported in ~1% of subjects with repeated monthly dosing; involves MC1R-mediated melanocyte activation; typically reversible on cessation
Severe nausea/emesis requiring antiemetic intervention: <5% of subjects in clinical trials

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients with established cardiovascular disease or MACE risk factors due to transient hemodynamic changes
Patients on antihypertensive therapy where a transient 12-hour BP elevation could be clinically significant
Patients with a personal or family history of melanoma due to MC1R-mediated melanocyte stimulation (theoretical risk; not confirmed causally)
Concurrent use of medications that significantly prolong QTc interval

Pre-administer 4 mg ondansetron (oral or sublingual) 30 minutes prior to PT-141 injection to substantially reduce nausea incidence (supported by clinical practice in Vyleesi prescribing guidelines)
Monitor blood pressure in at-risk patients for 12 hours post-dose
Use minimum effective dose (1 mg) and avoid exceeding 8 doses/month to limit cumulative MC1R stimulation
Rotate injection sites to minimize local pigmentation

Reference data

Specifications

Molecular formula: C50H68N14O10
Molecular weight: 1025.18 g/mol
Half-life: ~2.7 hours (terminal half-life ~120 hours due to extended tissue distribution)
Route: Subcutaneous, Nasal
Cycle length: On-demand; not typically used in continuous cycles. Maximum 1 dose per 24 hours, no more than 8 doses per month recommended.
Storage: Store lyophilized powder at -20°C for long-term storage. After reconstitution, refrigerate at 2–8°C and use within 30 days. Protect from light and avoid repeated freeze-thaw cycles.
Legal status: FDA-approved (as Vyleesi/bremelanotide) for HSDD in premenopausal women in the USA (2019). Research-grade PT-141 is sold legally as a peptide for research purposes in many jurisdictions; individual use regulations vary by country.

FAQ

Common questions

How does PT-141 differ mechanistically from PDE5 inhibitors?

PDE5 inhibitors (sildenafil, tadalafil) act peripherally by inhibiting cGMP degradation in corpus cavernosum smooth muscle, enhancing NO-mediated vasodilation and facilitating erection in response to sexual stimulation. PT-141 acts centrally via MC3R/MC4R in the hypothalamus to increase sexual motivation and desire through dopaminergic and oxytocinergic pathways — a fundamentally different and complementary mechanism. PT-141 can produce erections independent of sexual stimulation and may be effective in PDE5 non-responders.

What is the evidence base for PT-141 in males?

Phase II trials (Diamond et al., 2004; Annals of the New York Academy of Sciences) demonstrated significant erectile response in men with psychogenic and organic ED, including PDE5 non-responders, at doses of 4–7 mcg/kg intranasal. Subcutaneous formulation Phase II data also exist. The compound was not pursued to Phase III in males due to strategic focus on the female HSDD indication, which achieved FDA approval.

Is there any evidence for cardiovascular risk with chronic use?

The primary cardiovascular concern is the transient hemodynamic effect (BP elevation) per dose. A 52-week safety extension study supporting Vyleesi approval found no cumulative cardiovascular adverse event signal, though the study population excluded high-risk patients. Use is contraindicated in patients with significant cardiovascular disease per FDA labeling.

What is the evidence level?

This compound is classified as Clinical evidence. Randomized controlled trial data in humans exists and supports use in specific contexts.

Research

Research & sources

Clinical evidence

Current evidence for PT-141 is rated as Clinical evidence. Human clinical evidence supports the reported effects.

1. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial (RECONNECT) (2019) — Obstetrics & Gynecology 134(5):899–908
2. PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction (2004) — Annals of the New York Academy of Sciences 1035:330–41
3. Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (2019) — Obstetrics & Gynecology 134(5)
4. Melanocortin Receptors as Drug Targets for Disorders of Energy Homeostasis, Erectile Dysfunction, and Exocrine Gland Function (2003) — European Journal of Pharmacology 440(2–3):99–110

Explore

Often discussed alongside

BPC-157 · healing